Trial Profile
Safety and dose optimization for [11C] DMDPA as a PET imaging agent for evaluation of myocardial perfusion in subjects with known or suspected coronary artery disease (CAD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 26 May 2020
Price :
$35
*
At a glance
- Drugs Carbon-11 dimethyl diphenyl ammonium (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions
- 24 May 2020 Status changed from recruiting to completed.
- 03 Nov 2017 New trial record